Colgate-Palmolive Company (NYSE:CL) posted better-than-expected fourth-quarter earnings on Friday.
The company reported fourth-quarter adjusted earnings per share of 95 cents, beating the analyst consensus estimate of 91 cents. Quarterly sales of $5.230 billion, beating the Street view of $5.118 billion.
“Net sales and organic sales grew in every category during the quarter, led by strength in oral care and pet nutrition, excluding private label,” said CEO Noel Wallace.
Colgate-Palmolive forecasts fiscal 2026 sales of $20.79 billion to $21.61 billion, compared with analysts’ estimate of $20.98 billion.
Colgate-Palmolive shares gained 2% to trade at $92.11 on Monday.
These analysts made changes to their price targets on Colgate-Palmolive following earnings announcement.
- Deutsche Bank analyst Steve Powers maintained Colgate-Palmolive with a Hold and raised the price target from $83 to $90.
- Morgan Stanley analyst Dara Mohsenian maintained the stock with an Overweight rating and raised the price target from $87 to $100.
- B of A Securities analyst Bryan Spillane maintained Colgate-Palmolive with a Buy and raised the price target from $90 to $100.
- Piper Sandler analyst Michael Lavery maintained the stock with an Overweight rating and boosted the price target from $88 to $96.
- Evercore ISI Group analyst Robert Ottenstein maintained Colgate-Palmolive with an Outperform rating and raised the price target from $94 to $100.
- Wells Fargo analyst Chris Carey maintained the stock with an Equal-Weight rating and raised the price target from $86 to $94.
Considering buying CL stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments